Afluria Quadrivalent Market Report 2026

Afluria Quadrivalent Market Overview

• The Afluria Quadrivalent market growth in the historic period has been driven by limitations of trivalent influenza vaccines, recurring multi-strain flu outbreaks • Market expansion is supported by demand for broader strain coverage, increasing healthcare worker immunization • Growth Driver: Impact Of Rising Influenza Prevalence On The Growth Of The Afluria Quadrivalent Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Afluria Quadrivalent Market?

Afluria quadrivalent is a vaccine used to prevent infection from four different strains of the influenza virus: two strains of influenza A (H1N1 and H3N2) and two strains of influenza B. It is designed to protect against the flu during the flu season, which typically occurs annually. Afluria quadrivalent is administered via injection and is approved for use in individuals aged 6 months and older. The main clinical indications of afluria quadrivalent are seasonal influenza prophylaxis, high-risk population immunization, pediatric influenza prophylaxis, healthcare worker immunization. Seasonal Influenza Prophylaxis refers to the preventive use of vaccines, like the Afluria Quadrivalent, to reduce the risk of contracting seasonal influenza caused by the circulating strains of the influenza virus. The routes of administration are injection and nasal spray. The various age groups include adults, geriatric, and pediatrics, and distribution channels include hospitals and retail pharmacies, government suppliers, and others. The different end users encompass hospitals, public, private, clinics, and others.

What Is The Afluria Quadrivalent Market Growth Forecast?

The growth in the forecast period can be attributed to demand for broader strain coverage, increasing healthcare worker immunization, growth in pediatric vaccination programs, expansion of government procurement, innovation in vaccine delivery formats. Major trends in the forecast period include rising adoption of quadrivalent influenza vaccines, expanded protection against multiple flu strains, increased vaccination of high-risk populations, growth of government immunization initiatives, advancements in vaccine formulation technologies.

Global Afluria Quadrivalent Market Segmentation

1) By Clinical Indication: Seasonal Influenza Prophylaxis, High-Risk Population Immunization, Pediatric Influenza Prophylaxis, Healthcare Worker Immunization 2) By Route Of Administration: Injection, Nasal Spray 3) By Age Group: Adults, Geriatric, Pediatrics 4) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels 5) By End-User: Hospitals, Public, Private, Clinics, Other End-Users

What Are The Drivers Of The Afluria Quadrivalent Market?

The increasing prevalence of influenza is expected to propel the growth of the afluria quadrivalent market going forward. Influenza is a contagious respiratory illness caused by influenza viruses that can lead to mild to severe illness, including fever, cough, and body aches. The increasing prevalence of influenza is driven by factors such as the annual mutation of the virus, seasonal environmental conditions, and low vaccination coverage in certain populations. Afluria Quadrivalent plays a crucial role in combating the increasing prevalence of influenza by providing protection against four circulating flu strains, thereby reducing the risk of infection and mitigating the impact of seasonal outbreaks. For instance, in November 2024, according to the UK Health Security Agency, a UK-based government agency, influenza positivity rates in week 46 showed an increase, with a weekly average positivity rate of 3.9%, up from 3.3% the previous week. The highest positivity rates were observed in individuals aged 5 to 14, where the weekly average reached 11.6%, a rise from 8.8% in the previous week (week 45). Therefore, the increasing prevalence of influenza will drive the growth of the afluria quadrivalent industry. Increasing birth rates are expected to propel the growth of the afluria quadrivalent market going forward. The increase in birth rates can be attributed to various factors, including improved healthcare, government incentives, and changing societal attitudes. A higher number of births leads to a larger pediatric population that requires immunization. As birth rates rise, healthcare systems need to administer vaccines to more children to prevent influenza, leading to increased demand for vaccines like Afluria Quadrivalent. For instance, in October 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, there were 24,737 Aboriginal and Torres Strait Islander births registered in 2023, an increase of 349 babies from 2022. Thus, increasing birth rates are driving the growth of the afluria quadrivalent industry. The rising healthcare expenditure is expected to drive the growth of the afluria quadrivalent market going forward. Healthcare expenditure is the total spending on medical services, treatments, and healthcare resources, funded by governments, insurers, and individuals to ensure accessible and quality care. Afluria Quadrivalent benefits from rising healthcare expenditure as increase in funding enables broader access to seasonal influenza vaccination. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the rising healthcare expenditure is driving the growth of the afluria quadrivalent industry.

Key Players In The Global Afluria Quadrivalent Market

Major companies operating in the afluria quadrivalent market are Seqirus Inc.

Regional Insights

North America was the largest region in the afluria quadrivalent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Afluria Quadrivalent Market?

The afluria quadrivalent consists of sales of pre-filled syringes, vaccine vials, adjuvanted and unadjuvanted versions, flu vaccine kits, related packaging, and storage equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Afluria Quadrivalent Market Report 2026?

The afluria quadrivalent market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the afluria quadrivalent industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.